设为首页 加入收藏

TOP

Erbitux 5 mg/ml solution for infusioncetuximab(十三)
2013-10-09 16:44:38 来源: 作者: 【 】 浏览:8266次 评论:0
Hazard Ratio (95% CI)

0.401 (0.299, 0.536)

1.002 (0.732, 1.371)

p-value

<0.0001

0.9895

ORR

   

%

12.8

0

1.2

0

(95% CI)

(7.4, 20.3)

(-)

(0.0, 6.7)

(-)

p-value

<0.001

0.314  

BSC = best supportive care, CI = confidence interval, ORR = objective response rate (patients with complete response or partial response), OS = overall survival time, PFS = progression-free survival time
Squamous cell cancer of the head and neck
Immunohistochemical detection of EGFR expression was not performed since more than 90% of patients with squamous cell cancer of the head and neck have tumours that express EGFR.
Cetuximab in combination with radiation therapy for locally advanced disease
• EMR 62 202-006: This randomised study compared the combination of cetuximab and radiation therapy (211 patients) with radiation therapy alone (213 patients) in patients with locally advanced squamous cell cancer of the head and neck. Cetuximab was started one week before radiation therapy and administered at the doses described in section 4.2 until the end of the radiation therapy period.
The efficacy data generated in this study are summarised in the table below:

Variable/ statistic

Radiation therapy + cetuximab

Radiation therapy alone

 

(N=211)

(N=213)

Locoregional control

 

 

 

 

months, median (95% CI)

24.4

(15.7, 45.1)

14.9

(11.8, 19.9)

Hazard Ratio (95% CI)

0.68 (0.52, 0.89)

p-value

0.005

OS

       

months, median (95% CI)

49.0

(32.8, 62.6+)

29.3

(20.6, 42.8)

Hazard Ratio (95% CI)

0.74 (0.56, 0.97)

p-value

0.032  

CI = confidence interval, OS = overall survival time, a '+' denotes that the upper bound limit had not been reached at cut-off
Patients with a good prognosis as indicated by tumour stage, Karnofsky performance status (KPS) and age had a more pronounced benefit, when cetuximab was added to radiation therapy. No clinical benefit could be demonstrated in patients with KPS  80 who were 65 years
以下是“全球医药”详细资料
Tags: 责任编辑:admin
首页 上一页 10 11 12 13 14 15 16 下一页 尾页 13/17/17
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Cystadane Pulver 下一篇Erbitux 5mg/ml inopha Infusions..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位